Merck & Co. says the $3.85bn (€2.8bn) acquisition of Idenix will springboard its oral hepatitis C programme but according to an analyst is unlikely to threaten Gilead’s $1,000 pill Sovaldi.
Hope may be on the horizon in the quest for a preventative
hepatitis C virus (HCV) vaccine after scientists said they have
been able to identify and characterise the antibody responses to
the virus.
A long-acting biologic being co-developed by Novartis to treat
chronic hepatitis C virus (HCV) has triggered a $40m (€29.3m)
milestone for its development partner after clearing Phase II
trials in April.
Vertex Pharmaceuticals has released early results on its
first-in-class hepatitis C drug that show it has the potential to
shorten treatment times for those suffering from the hard-to-treat
genotype-1.
Bayer Diagnostics and Innogenetics have launched an assay that
allows genotyping for the Hepatitis C Virus (HCV), permitting
broader identification of HCV genotypes with improved accuracy, not
possible by current HCV genotyping products.
Celera Genomics announces its new test that is used for genotyping
of the hepatitis C virus (HCV) has obtained regulatory approval for
commercial sale in Europe, signifying the first real-time test for
genotyping the HCV virus to...
Intermune and Array BioPharma have agreed to extend and expand
their current Hepatitis C (HCV) drug discovery collaboration. The
main area of focus, protease inhibitors, represents a promising
class of drugs for HCV because of its...
Intermune has announced the results of preclinical data on the
specificity and tolerability of two potent and selective small
molecule inhibitors of the hepatitis C virus (HCV). The findings
are significant, as they have previously...
Vertex Pharmaceuticals have announced the latest results that
indicate the investigational oral hepatitis C virus (HCV) protease
inhibitor VX-950 was well tolerated and demonstrated potent
antiviral activity in a Phase Ib clinical...
New treatment strategies for the hepatitis C virus (HCV) based on a
specific combination of genes that directly give protection against
HCV without the necessity for additional treatment for a virus that
affects 170 million people...